Quest PharmaTech Inc. (CVE:QPT – Get Free Report) shares hit a new 52-week low during trading on Thursday . The stock traded as low as C$0.02 and last traded at C$0.02, with a volume of 7000 shares changing hands. The stock had previously closed at C$0.04.
Quest PharmaTech Stock Performance
The company has a debt-to-equity ratio of 1.51, a current ratio of 0.26 and a quick ratio of 0.52. The firm has a fifty day simple moving average of C$0.03 and a 200 day simple moving average of C$0.04. The company has a market capitalization of C$3.38 million, a price-to-earnings ratio of -0.17 and a beta of 0.29.
About Quest PharmaTech
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Featured Articles
- Five stocks we like better than Quest PharmaTech
- What is the Australian Securities Exchange (ASX)
- MarketBeat Week in Review – 4/22 – 4/26
- Most active stocks: Dollar volume vs share volume
- 3 Stocks Leading the U.S. Agriculture Comeback
- How to buy stock: A step-by-step guide for beginnersÂ
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.